Boomi Appoints New Leaders To Support Rapid Customer Growth After Successful Spin Off As A Newly Independent Company
13.6.2022 16:20:00 EEST | Business Wire | Press release
Boomi™, the intelligent connectivity and automation leader, today announced the appointment of Madeline Ling as chief financial officer (CFO), Marcy Campbell as chief revenue officer (CRO), and Fran Wilson as chief marketing officer (CMO), effective immediately. Additionally, Emmy award-winning news journalist Christa Delcamp joins Boomi to support public relations and media strategy, and James Dyson joins the company to lead Global Diversity, Equity, and Inclusion Talent Acquisition.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220613005227/en/
Boomi Attracts Industry Leaders For Next Stage Of Growth (Graphic: Business Wire)
“Boomi's recent launch as a standalone company – coupled with our high growth and cutting-edge, cloud-based technology – provides the opportunity to build our leadership team as part of a much larger expansion, with several hundred new hires coming onboard this year,” said David Meredith, CEO at Boomi. “Our industry-leading platform and award-winning culture enabled us to recruit top, globally-minded talent, with a demonstrated track-record of achievement, and a passion to accelerate our mission to make the world a better place by connecting everyone to everything, anywhere.”
The new leadership appointments come after Boomi's recent independence backed by premier private equity firms, Francisco Partners and TPG, in a $4 billion transaction. As a global software as a service (SaaS) category leader with more than 20,000 customers – Boomi touts a growing user community of over 100,000 members, a worldwide network of more than 800 partners, and one of the largest arrays of global system integrators (GSI) in the iPaaS space, which includes Accenture, Deloitte, SAP, and Snowflake, as well as the three largest cloud providers, Amazon Web Services, Google, and Microsoft, among others.
Boomi has been positioned as a Leader in the Gartner® Magic Quadrant™ for enterprise platform as a service (EiPaaS)1 for eight consecutive years. The company recently received the Gold Globee® Award in the Platform as a Service (PaaS) category, and has garnered numerous awards for being an employer of choice, including a recent listing as one of Inc. Magazine’s Best Workplaces. As the company continues to scale rapidly to meet global, enterprise demand for digital connectivity, integration, and automation, Boomi plans to hire several hundred new team members this year to accelerate all functions of the business.
BOOMI ATTRACTS WORLD-CLASS TALENT:
Madeline Ling, CFO
Ling holds a MBA from Stanford Graduate School of Business, and brings nearly 25 years of experience leading equity-backed, global enterprise organizations through strategic and international growth. She has held multiple CFO roles throughout her career, including international assignments overseas. Ling most recently served as corporate CFO for a Hellman and Friedman (H&F) PE-backed portfolio company, and held previous roles at VMware, The Boston Consulting Group, and Intel.
Marcy Campbell, CRO
Campbell brings to Boomi over 30 years of experience leading large-scale, go-to-market organizations for global companies ranging from Fortune 500 to venture-backed technology firms. She most recently served as senior vice president at PayPal where she led global sales, professional services, and operations. At Boomi, Campbell will spearhead the company’s revenue-generating strategies with a focus on driving fast growth, while continuing to deliver customer value.
Fran Wilson, CMO
With more than 20 years of successful experience in SaaS and B2B enterprise software organizations, Wilson provided marketing leadership through Red Hat’s initial public offering (IPO), and during its rapid revenue growth from $400 million to more than $4 billion, culminating in its sale to IBM for $34 billion.
Christa Delcamp, Public Relations and Media Strategy
Delcamp brings over two decades of experience in public relations, journalism, content creation, and communications, across a variety of platforms, including digital/social, NBC and CBS-owned and operated stations, radio/podcasting, and print. An Emmy award-winning news journalist, Delcamp’s extensive expertise in telling impactful stories will help Boomi increase market awareness of its industry-leading platform and important mission to connect the world.
James Dyson, Global Diversity, Equity, and Inclusion (DE&I) Talent Acquisition
Dyson brings over 20 years of experience leading and managing talent acquisition at global companies, including Accenture. In his role, Dyson will leverage his deep expertise and extensive international network to support Boomi’s rapid growth and continue to build the company’s award-winning culture.
Additional Resources
- Check out open roles at Boomi
- Learn more about the Boomi AtomSphere Platform
- Explore the Boomiverse Community
- Follow Boomi on Twitter, LinkedIn, Facebook, and YouTube
Gartner Disclaimer:
Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER and Magic Quadrant are registered trademarks and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Note: Boomi was recognized as Dell Boomi from 2014 to 2019.
About Boomi
Boomi instantly connects everyone to everything, anywhere with its cloud-native, unified, open, and intelligent platform. Boomi's integration platform as a service (iPaaS) is trusted by more than 20,000 customers globally for its speed, ease-of-use, and lower total cost of ownership. As the pioneer at fueling intelligent use of data, Boomi's vision is to make it quick and easy for customers and partners to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com.
© 2022 Boomi, LP. Boomi, the ‘B’ logo, Boomiverse, and AtomSphere are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
________________________
1 Gartner, Magic Quadrant for Enterprise Integration Platform as a Service, Eric Thoo, Keith Guttridge, Bindi Bhullar, Shameen Pillai, Abhishek Singh, September 29, 2021
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005227/en/
Contact information
Kristen Walker
Global Corporate Communications
kristenwalker@boomi.com
+1-415-613-8320
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
